Novelty is the first and most fundamental criterion for patentability under Indian patent law. Before any question of inventive step, industrial applicability or statutory exclusion arises, the threshold question is always the same – is the invention new? If it is not, the inquiry ends there. No amount of technical sophistication, commercial significance or inventive ingenuity can rescue an invention that has already been disclosed to the public.
The requirement of novelty is not a mere formality. It is the juridical foundation upon which the entire patent system rests. A patent is a bargain between the inventor and the public. The inventor receives a limited period of exclusivity. In return, the inventor discloses the invention fully and enriches the public domain. That bargain is only justified if what is being disclosed is genuinely new. Where the invention is already known, no disclosure is being made. The public is receiving nothing in exchange for the monopoly it is granting. The novelty requirement enforces the integrity of this exchange.
Indian patent law imposes one of the strictest novelty standards in the world. It follows a universal absolute novelty standard under which prior disclosure anywhere in the world, in any form, at any time before the priority date, can defeat the novelty of an invention. Understanding how this standard operates – its statutory basis, its scope, the concept of anticipation, its recognised exceptions and its practical implications for prosecution – is essential for every patent practitioner, applicant and researcher engaging with the Indian patent system.
The Statutory Framework
The requirement of novelty flows from the definition of invention itself. Section 2(1)(j) of the Patents Act, 1970 defines an invention as a new product or process involving an inventive step and capable of industrial application. The word new is not merely descriptive. It is a statutory precondition. An invention that is not new does not satisfy the definition and therefore cannot be patented regardless of any other consideration.
Section 2(1)(l) of the Act defines new invention as any invention or technology which has not been anticipated by publication in any document or used in the country or elsewhere in the world before the date of filing of the patent application with complete specification. The definition makes three things clear. First, novelty is assessed as on the date of filing of the complete specification, or the priority date where applicable. Second, anticipation may arise from either publication or prior use. Third, the geographical scope is unlimited – anticipation anywhere in the world suffices.
The Act does not confine prior art to Indian publications or Indian use. A disclosure in a journal published in the United States, a patent specification filed in Japan, a product sold in Germany, a process demonstrated at a conference in the United Kingdom – all of these constitute prior art capable of destroying novelty in India. This absolute novelty standard reflects India’s obligations under the TRIPS Agreement and its integration with the global patent system.
Sections 29 to 34 of the Patents Act elaborate the law of anticipation by specifying particular circumstances in which a prior disclosure does and does not defeat novelty. These provisions read together with Section 2(1)(l) constitute the complete statutory framework governing novelty in India.
The Concept of Anticipation
Anticipation is the legal mechanism through which prior art destroys novelty. An invention is said to be anticipated when it has been previously disclosed in the prior art in a manner that would enable a person skilled in the relevant art to perform or reproduce the invention. The standard is one of enablement – mere mention or theoretical reference is not enough. The prior disclosure must be sufficiently complete that a skilled person could, on the basis of that disclosure alone, arrive at the claimed invention.
The Supreme Court of India articulated the foundational principle with clarity in Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries (1978)
“The fundamental principle of patent law is that a patent is granted only for an invention which must be new and useful. That is to say, it must have novelty and utility. It is essential for the validity of a patent that it must be the inventor’s own discovery as opposed to mere verification of what was already known before the date of the patent.”
This formulation captures the essence of the novelty requirement. The patent must represent the inventor’s own discovery – something that was not previously known. Verification, confirmation or rediscovery of what already exists in the public domain does not qualify.
For anticipation to occur, the prior art document or prior use must disclose all the essential features of the claimed invention. Partial disclosure is not anticipation. If the prior art discloses some but not all features of the claim, the claim may survive a novelty objection – though it may still face an obviousness challenge on inventive step grounds. The all-elements rule governs novelty analysis: every element of the claim must be found, either expressly or inherently, in a single prior art reference.
This single-reference rule is critical. Unlike the analysis for inventive step, where multiple prior art references may be combined to argue obviousness, novelty must be defeated by a single disclosure. A combination of references cannot together destroy novelty unless each individual reference, taken alone, discloses the complete invention.
Sources of Prior Art Under the Patents Act
Prior Publication
The most common source of anticipation is prior publication. Any document that was publicly available before the priority date and that discloses the claimed invention constitutes anticipating prior art. The range of qualifying documents is broad and includes earlier patent specifications filed anywhere in the world, scientific and technical journal articles, conference papers and proceedings, textbooks and academic publications, product catalogues, manuals and technical datasheets, and online publications and databases.
The document must have been publicly accessible before the priority date. A document that existed but was kept confidential does not constitute prior art. Publication requires that the document was available to at least one member of the public who was free to make use of the information without restriction.
Section 13 of the Patents Act specifically requires the examiner to search for prior art during examination. The examiner considers published patent specifications in India and other countries, as well as other published documents, in determining whether the claimed invention is anticipated.
Prior Use
Prior use of an invention in public, whether in India or elsewhere, before the priority date constitutes anticipating prior art under Section 2(1)(l). Use in a commercial context, use in a manufacturing process, or use in a publicly accessible demonstration can all constitute prior art if they disclose the essential features of the claimed invention sufficiently for a skilled person to reproduce it.
Secret use does not constitute prior art. Use that is confined to a confidential research environment, protected by obligations of secrecy, does not destroy novelty. The key is whether the public has had access to the disclosure.
Prior Knowledge
Inventions that form part of the general knowledge or state of the art in a particular field – even if not recorded in a specific document – may be considered prior art in appropriate circumstances. Traditional knowledge is specifically addressed in the Patents Act through Section 3(p), which excludes from patentability inventions that are based on traditional knowledge or aggregation or duplication of known properties of traditionally known components.
Sections 29 to 34: Specific Anticipation Provisions
Section 29 – Anticipation by Prior Publication
Section 29 provides that an invention claimed in a complete specification shall not be deemed to have been anticipated by reason only of the publication of the matter in a document, if the Controller is satisfied that the disclosure was made without the knowledge or consent of the applicant or the applicant’s predecessor in title, and the application was filed as soon as reasonably practicable after knowledge of the disclosure reached the applicant.
This provision protects applicants against unauthorised disclosures. If a third party reveals the invention – whether through breach of confidentiality, industrial espionage or inadvertent disclosure – and the applicant files promptly upon learning of this, the disclosure does not defeat novelty. The critical requirements are absence of consent and prompt filing upon discovery.
Section 30 – Anticipation by Communication to Government
Section 30 provides that disclosure to the Central Government or to any person authorised by the Government for the purpose of investigating whether the invention should receive government support shall not constitute anticipating prior art. Communications made in confidence to government authorities for evaluation or security clearance purposes are protected.
Section 31 – Anticipation by Public Display
Section 31 provides a grace period of limited scope for certain public disclosures. Where an invention is displayed at an industrial or other exhibition notified by the Central Government, or communicated to a learned society or published with the consent of the applicant by such a society, the disclosure does not defeat novelty provided the application is filed within twelve months of the disclosure.
This provision is narrow and carefully circumscribed. It applies only to exhibitions notified by the Central Government under the Patents Act and to communications to recognised learned societies. It does not create a general grace period. An inventor who discloses the invention in a publication, press release, website, conference paper or product launch outside the scope of Section 31 will find that the disclosure destroys novelty regardless of how promptly the application is subsequently filed. This is a critical distinction from the grace period provisions available in jurisdictions like the United States, where a broader one-year grace period applies to the inventor’s own disclosures.
Section 32 – Anticipation by Use and Publication after Provisional Specification
Section 32 addresses the situation where use or publication occurs after the filing of a provisional specification but before the filing of the complete specification. Such use or publication does not constitute anticipation. The provisional filing establishes a priority date, and disclosures made after that priority date do not affect novelty.
Section 33 – Anticipation by Prior Claiming
Section 33 deals with the situation where two applications are pending simultaneously, and the prior application has an earlier priority date. The earlier application, once published, constitutes prior art against the later application even if both are pending at the time of examination. This prevents two patents from being granted for the same invention when both applications were filed before either was published.
Section 34 – Priority Dates
Section 34 provides for the determination of priority dates in relation to anticipation. Where the Patents Act requires determination of whether an invention was known or used before a relevant date, the relevant date is the date of filing of the complete specification unless a priority date has been claimed under the Paris Convention or the PCT route.
Prior Art and the Priority Date
The priority date is the date against which novelty is assessed. Typically, this is the date of filing the complete specification in India. However, where an applicant has first filed a patent application in a country that is a member of the Paris Convention, the Indian application may claim the priority date of that earlier foreign application provided the Indian application is filed within twelve months of the foreign filing date.
This Convention priority mechanism is of considerable practical importance. An applicant who files first in the United States, Japan, Europe or any other Paris Convention country and then files in India within twelve months effectively backdates the novelty assessment to the date of the first foreign filing. Disclosures made between the foreign filing date and the Indian filing date do not constitute prior art against the Indian application.
Similarly, under the Patent Cooperation Treaty route, an international application designating India enjoys a priority date from the date of the international filing. The national phase entry in India must be completed within the prescribed time limits – generally thirty-one months from the priority date – and the novelty assessment is conducted as of the international filing date.
Absolute Novelty vs Local Novelty
It is important to appreciate the distinction between absolute novelty – which India follows – and local novelty, which some older or less developed patent systems followed historically. Under a local novelty standard, only prior art available within the jurisdiction would defeat novelty. Use or publication in another country would be irrelevant.
India’s adoption of absolute novelty since the Patents Act of 1970 means that the relevant prior art universe is global. There is no safe harbour for an invention that has been disclosed abroad but not yet in India. An Indian applicant seeking to patent a product that is already commercially available in another country will find that the foreign availability defeats novelty under Indian law, even if no Indian consumer has encountered the product.
This standard creates both rigour and fairness. It prevents the Indian patent system from being used to grant monopolies on inventions that are already part of the global state of the art, and it aligns Indian patent practice with international standards.
Novelty in Examination Practice
The First Examination Report
The examination of novelty is central to the First Examination Report issued by the Patent Office. The examiner searches prior art databases – including published patent specifications from multiple patent offices and scientific literature – and identifies documents that disclose the claimed invention or essential elements of it.
Where the examiner identifies a prior art document that anticipates one or more claims, a novelty objection is raised. The applicant must respond within the prescribed time by either amending the claims to distinguish the invention from the prior art, or by arguing that the cited prior art does not in fact anticipate the claims because it does not disclose all the essential features or does not enable the skilled person to perform the invention.
Responding to Novelty Objections
A well-structured response to a novelty objection requires precise claim-by-claim analysis. The applicant must demonstrate that the cited prior art reference does not disclose each and every element of the claimed invention. Even if nine out of ten features are found in the prior art, the absence of the tenth feature is sufficient to overcome the novelty objection – though the applicant must then be prepared to address an inventive step objection based on the distinction.
Claim amendments under Section 57 and Section 59 are frequently necessary during prosecution. The amendments must narrow the claim to distinguish it from the prior art without broadening the scope beyond the original disclosure. Over-narrowing a claim to escape a prior art reference may inadvertently surrender claim scope that the applicant intended to protect. Prosecution strategy requires balancing these competing considerations.
The Delhi High Court emphasised the importance of precise claim analysis in the context of anticipation in Cipla Ltd. v. F. Hoffmann-La Roche Ltd. (2009), where the court examined whether the prior art disclosed not merely related compounds but the specific compound that was the subject of the patent claim. The case illustrated the significance of specificity – prior art that discloses a genus does not necessarily anticipate a species within that genus, and the court’s analysis of the anticipation question required careful examination of what was actually disclosed.
Novelty of Selection Inventions
A selection invention arises where an inventor selects a specific member or subgroup from a broader class or range already disclosed in the prior art, and demonstrates that the selected member or subgroup has a surprising or unexpected property that was not previously known. Indian patent law, following the general principles of anticipation, permits selection inventions where the specific selection was not individually disclosed in the prior art and where the unexpected properties are demonstrated by appropriate evidence.
The relationship between selection inventions and Section 3(d) is significant in the pharmaceutical context. Even where a selection would otherwise be novel as a matter of patent law, if it constitutes a new form of a known substance – such as a polymorph, isomer, metabolite or derivative – it must demonstrate enhanced efficacy to escape the Section 3(d) exclusion. The Supreme Court’s analysis in Novartis AG v. Union of India (2013) is the seminal authority on this intersection.
In that case, Novartis sought a patent for the beta crystalline form of imatinib mesylate, the active compound in the cancer drug Gleevec. The Supreme Court held that the beta crystalline form was a new form of a known substance – imatinib – and that under Section 3(d) it was required to demonstrate enhanced therapeutic efficacy over the known substance. The Court found that improved bioavailability, without evidence of enhanced therapeutic efficacy, was insufficient. The case is primarily a Section 3(d) decision, but its analysis of what constitutes a known substance and what constitutes a new form has direct implications for how novelty and selection are assessed in pharmaceutical patent prosecution.
Novelty Distinguished from Inventive Step
Novelty and inventive step are distinct requirements, although they are related and are frequently addressed together during prosecution. The distinction is fundamental and must be clearly understood.
Novelty asks whether the invention has been previously disclosed. It is a binary question. Either the prior art discloses the complete invention – in which case there is no novelty – or it does not, in which case the novelty requirement is satisfied. A single prior art reference must disclose all elements of the claimed invention to destroy novelty.
Inventive step asks whether the invention, even if not previously disclosed in its entirety, would have been obvious to a person skilled in the art having regard to the prior art. Inventive step allows the combination of multiple references and the application of common general knowledge. An invention may be novel – because no single reference discloses all its features – yet still lack inventive step because the combination of features was obvious.
The Supreme Court in Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries (1978) articulated the distinction:
“To be patentable an improvement must not be obvious to a skilled worker in the relevant art at the relevant date. The improvement must involve a ‘technical advance’ as compared to what was known before.”
This formulation makes clear that novelty is the gateway requirement – if novelty fails, the invention cannot be patented – but novelty alone is not sufficient. The invention must also clear the inventive step hurdle. An analysis of patentability that establishes novelty without addressing inventive step is incomplete.
Novelty in Opposition and Revocation Proceedings
Lack of novelty is one of the most frequently invoked grounds in both pre-grant and post-grant opposition proceedings under Section 25 of the Patents Act. Any person may file a pre-grant opposition after publication of the application but before grant, relying on prior art that the examiner may not have considered. Post-grant oppositions may similarly raise anticipation based on prior art that was not before the examiner during prosecution.
The opponent bears the initial burden of establishing a prima facie case of anticipation by identifying the prior art and demonstrating how it discloses the essential features of the contested claim. Once a prima facie case is established, the burden shifts to the patentee to distinguish the prior art or to argue that the disclosure does not enable the skilled person to perform the invention.
Revocation proceedings under Section 64 similarly permit anticipation as a ground. A High Court may revoke a patent on the ground that the invention was anticipated by prior publication or prior use. In Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd. (2015), the Delhi High Court engaged in detailed analysis of the prior art cited in revocation proceedings, examining the scope of the prior art disclosures and whether they individually anticipated the claims of the patent in suit. The case reinforced that anticipation requires complete disclosure of all claim elements in a single reference and that the court must carefully compare the claim language against the prior art disclosure.
Novelty in the Context of Traditional Knowledge
Indian patent law takes a distinctive approach to the relationship between novelty and traditional knowledge. Section 3(p) excludes from patentability inventions that are traditional knowledge or that are based on aggregation or duplication of known properties of traditionally known components. The Traditional Knowledge Digital Library, established by the Government of India, contains codified records of traditional knowledge drawn from ancient Indian texts and practices. This database is made available to patent offices in multiple countries as prior art to prevent the grant of patents for inventions that are, in substance, traditional knowledge.
The TKDL has successfully been used to defeat patent applications in India and abroad. In the context of novelty, traditional knowledge documented in the TKDL constitutes prior art regardless of whether it appeared in a conventional patent document or scientific journal. The Ayurvedic, Unani, Siddha and Yoga knowledge documented in the library forms part of the prior art universe against which novelty of pharmaceutical and related inventions is assessed.
Practical Implications for Patent Prosecution
A clear understanding of the novelty requirement has direct and immediate practical implications for patent prosecution strategy in India.
Prior art searching before filing is not optional – it is essential. A thorough prior art search conducted before filing the complete specification allows the applicant to draft claims that are clearly distinguished from the prior art, to anticipate objections that are likely to arise during examination, and to make an informed decision about whether the invention has a realistic prospect of surviving examination. Filing without a prior art search is a risk that experienced practitioners do not take.
Claim drafting strategy must be informed by the prior art landscape. Independent claims should be drafted to cover the broadest scope that the prior art permits. Dependent claims should capture narrower, preferred embodiments. If broad claims are subsequently rejected on novelty grounds, narrower dependent claims may survive and still provide meaningful protection. A claim structure that anticipates the prior art objection from the outset is far more resilient than one that requires wholesale amendment during prosecution.
The priority date must be secured and maintained. Where an applicant has made a disclosure – even a limited one – before filing, the priority date from the earliest possible filing becomes critical. Convention priority from an earlier foreign filing should be claimed wherever available. The twelve-month window under the Paris Convention for filing in India after a foreign priority application must be managed carefully.
Provisional applications serve a valuable role in securing an early priority date. Filing a provisional specification as soon as the invention is sufficiently developed secures the priority date even before the complete specification is ready. The complete specification must be filed within twelve months of the provisional. This mechanism is particularly valuable for applicants who are actively developing or refining the invention after the initial conception.
Conclusion
Novelty is not merely the first criterion for patentability. It is the conceptual bedrock on which the entire patent system is built. The Indian Patents Act, 1970 adopts an absolute novelty standard that is among the most rigorous in the world. Prior disclosure anywhere in the world, in any form, before the priority date constitutes anticipating prior art. The concept of anticipation requires that a single prior art reference disclose all the essential features of the claimed invention in a manner that enables a person skilled in the art to perform it.
Sections 29 to 34 of the Act provide a carefully structured framework governing specific anticipation scenarios, recognising limited exceptions for unauthorised disclosures, government communications and disclosures at notified exhibitions while leaving no general grace period for an inventor’s own prior publications. The priority date mechanism, available through the Paris Convention and PCT routes, allows applicants to backdate the novelty assessment to an earlier foreign filing.
Case law from the Supreme Court and High Courts has consistently reinforced that novelty must be assessed rigorously, that anticipation requires complete disclosure of the claimed invention in a single reference, and that distinctions between novelty and inventive step must be maintained with precision.
For practitioners, applicants, researchers and students engaged with Indian patent law, novelty is not a threshold that can be assumed or glossed over. It demands careful prior art searching, disciplined claim drafting, strategic priority management and a thorough understanding of how the Indian Patent Office and courts interpret and apply the anticipation doctrine. An invention that cannot establish novelty cannot enter the Indian patent system at all – making novelty not merely the first question but, in many cases, the only question that matters.
- The Patents Act, 1970 (as amended up to 2024) – https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_113_1_The_Patents_Act__1970___incorporating_all_amendments_till_1-08-2024.pdf
- The Patents Rules, 2003 – https://ipindia.gov.in/patents.htm
- Manual of Patent Office Practice and Procedure – https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_15_1_manual-of-patent-office-practice-and-procedure.pdf
- TRIPS Agreement (WTO Official) – https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries (1978) – https://indiankanoon.org/doc/371631/
- Novartis AG v. Union of India (2013) – https://indiankanoon.org/doc/165776436/
- Cipla Ltd. v. F. Hoffmann-La Roche Ltd. (2009) – https://indiankanoon.org/doc/1368968/
- Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd. (2015) – https://indiankanoon.org/doc/91709044/
- Traditional Knowledge Digital Library – https://www.tkdl.res.in/
Compulsory Licensing Copyright Act Copyright Act 1957 Copyright Enforcement Copyright Infringement Copyright Law Copyright Licensing Copyright Registration Copyright Rules CRI Guidelines Deceptive Similarity Fair Dealing Defence Rejected Goodwill Indian IP Framework Indian Patent Act Indian Patent Law Indian Trademark Law Intellectual Property Law Interim Injunction Inventive Step IP Law India Passing Off Patent Claims Patent Enforcement Patent Examination Patent Infringement Patent law Patent Revocation Patent Rule Pharmaceutical Patents Section 3 Section 11 Section 13 Section 29 The Patent Act 1970 Trademark Dilution Trademark Enforcement Trademark Infringement Trademark Litigation Trademark Registration Trade Marks Act 1999 Trade Marks Rules 2017 TRIPS Agreement TRIPS Compliance Well-Known Trademark